None

Pexidartinib is a targeted therapy used to treat idiopathic multisegmental chondrosarcoma (TGCT). However, some patients may develop drug resistance, in which the drug becomes less effective on tumor cells. The mechanisms of drug resistance may be multifaceted and include several possible scenarios.

Gene mutations in tumor cells may cause pesidartinib's target to change, making the drug less effective. These mutations may affect the affinity of drug binding targets or interfere with the normal function of signaling pathways. Certain tumor cells may evade the therapeutic effects of pexidartinib by transforming into other cell types. This transformation may lead to changes in the growth, proliferation and infiltration capabilities of cells, causing the drug to lose its inhibitory effect. After the development of drug resistance, tumor cells may maintain their survival and proliferation capabilities through other signaling pathways. These alternative pathways can bypass the effects of pesidartinib and render tumor cells resistant to the drug. Cells, molecules, and extracellular matrix in the tumor microenvironment may interact with tumor cells and promote the development of drug resistance. These changes may include immune evasion mechanisms, alterations in angiogenesis, and changes in cell-cell interactions.

If it is necessary to deal with pesidartinib resistance, genetic analysis of the patient's tumor samples can be used to understand the resistance mechanism and formulate individualized treatment plans for the patient, such as combination therapy, immunotherapy, clinical trials, etc. Pesidartinib is not marketed in the country. There is less information on the price and other related information of pexidartinib after it is launched overseas. For more drug information and specific prices, please consult the medical consultant.